A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Novālent is HACCP Certified

December 9, 2020

Novālent reports its facilities are Hazard Analysis Critical Control Point (HACCP) certified.

“Earning the GMP/HACCP certification in our manufacturing plant is a competitive advantage. This is a big deal when it comes to adding another layer of food safety for our food and beverage customers. In today’s world where there is a heightened awareness for food protection, this certification becomes extremely valuable to the entire food chain.” Mike Motta, Chief Commercial Officer at Novālent, explains.

HACCP certification is an internationally recognized list of requirements established by the Food Safety Modernization Act (FSMA) and Global Food Safety Initiatives (GFSI) standards.

Achieving the certification confirms a company employs effective control of food safety throughout its processes. The principles of this certification are often used to update food safety legislation in countries around the world.

Novālent was assisted in this achievement by Darryle Guarino, CEO at GFSC Group, Inc. who says going through this process is indicative of a modern biochemical company’s dedication to safety.

“Spending time on this certification—and it is a significant time and resources investment—is indicative of a company seeking to modernize its approach to food safety requirements.”

Novālent film technology is for use as a residual antimicrobial under EPA and FDA regulations to preserve food contact surfaces and is used by leading firms including PepsiCo, Sabra, and Pilgrims. Novālent antimicrobial creates an invisible film that stays active and anchored through day to day operations. One application lasts up to 90 days and through multiple cleaning cycles. The company also offers a hand sanitizer.

SourceNovālent
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
The addition of Olink to the Synexa Life Sciences technology portfolio demonstrates our continued commitment to strengthening our biomarker and bioanalysis capabilities across several expertise areas including oncology, immuno-oncology, infectious diseases and more.

By using this website you agree to accept Medical Device News Magazine Privacy Policy